Pemphigus Vulgaris Market to Observe Impressive Growth During the Forecast Period (2022-2032), Evaluates DelveInsight | Key Companies – Topas Therapeutics, ARGX-113, Efgartigimod, Cabaletta Bio

March 06 23:35 2023
Pemphigus Vulgaris Market to Observe Impressive Growth During the Forecast Period (2022-2032), Evaluates DelveInsight | Key Companies - Topas Therapeutics, ARGX-113, Efgartigimod, Cabaletta Bio
The Pemphigus Vulgaris market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Pemphigus Vulgaris pipeline products will significantly revolutionize the Pemphigus Vulgaris market dynamics.

DelveInsight’s “Pemphigus Vulgaris Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Pemphigus Vulgaris, historical and forecasted epidemiology as well as the Pemphigus Vulgaris market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.


The Pemphigus Vulgaris market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 


To Know in detail about the Pemphigus Vulgaris market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pemphigus Vulgaris Market Insights


Pemphigus Vulgaris Overview

Pemphigus vulgaris (PV) is a potentially fatal autoimmune, intraepithelial disease characterized by flaccid blisters and erosions of the skin and mucous membranes and histologically by acantholysis. It is mediated by circulating desmoglein-reactive autoantibodies directed against keratinocyte cell surfaces.


Some of the key facts of the Pemphigus Vulgaris Market Report: 

  • The Pemphigus Vulgaris market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • Pemphigus Vulgaris has an average age of onset of 40–60 years (Joly and Litrowski 2011). It has a prevalence of around 30,000 cases in the US and an incidence of 1–10 new cases per 1 million people (Pemphigus. Pemphigus Pemphigoid Foundation (IPPF) 2014)
  • Key Pemphigus Vulgaris Companies: Topas Therapeutics, ARGX-113, Efgartigimod, Cabaletta Bio, and others
  • Key Pemphigus Vulgaris Therapies: TPM203, Argenx BVBA, DSG3-CAART, and others
  • The Pemphigus Vulgaris epidemiology based on gender analyzed that Pemphigus Vulgaris a higher percentage of diagnosed prevalence was observed for females, in comparison to males


Get a Free sample for the Pemphigus Vulgaris Market Report –


Key benefits of the Pemphigus Vulgaris Market report:

  1. Pemphigus Vulgaris market report covers a descriptive overview and comprehensive insight of the Pemphigus Vulgaris Epidemiology and Pemphigus Vulgaris market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Pemphigus Vulgaris market report provides insights on the current and emerging therapies.
  3. Pemphigus Vulgaris market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Pemphigus Vulgaris market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Pemphigus Vulgaris market.


Download the report to understand which factors are driving Pemphigus Vulgaris epidemiology trends @ Pemphigus Vulgaris Epidemiological Insights 


Pemphigus Vulgaris Market  

The dynamics of the Pemphigus Vulgaris market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032. 

“Of the emerging therapies, the most anticipated product to get launched is Efgartigimod. Another emerging drug TPM203 is evaluated in the phase I clinical trial in subjects with PV at seven sites in Germany.”


Pemphigus Vulgaris Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.


Pemphigus Vulgaris Epidemiology Segmentation:

The Pemphigus Vulgaris market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Pemphigus Vulgaris
  • Prevalent Cases of Pemphigus Vulgaris by severity
  • Gender-specific Prevalence of Pemphigus Vulgaris
  • Diagnosed Cases of Episodic and Chronic Pemphigus Vulgaris


Pemphigus Vulgaris Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Pemphigus Vulgaris market or expected to get launched during the study period. The analysis covers Pemphigus Vulgaris market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Pemphigus Vulgaris Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.


Discover more about therapies set to grab major Pemphigus Vulgaris market share @ Pemphigus Vulgaris market forecast 


Pemphigus Vulgaris Therapies and Key Companies

  • TPM203: Topas Therapeutics
  • Argenx BVBA: ARGX-113/Efgartigimod
  • DSG3-CAART: Cabaletta Bio


Pemphigus Vulgaris Market Drivers

  • The rise in the prevalence, Growing geriatric population and risk factors, Drug-induced Pemphigus Vulgaris
  • The recent approval of MabThera/Rituxan
  • Rise in the awareness and support from advocacy groups and healthcare agencies
  • Updated diagnostic and treatment guidelines


Scope of the Pemphigus Vulgaris Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Pemphigus Vulgaris Companies: Topas Therapeutics, ARGX-113, Efgartigimod, Cabaletta Bio, and others
  • Key Pemphigus Vulgaris Therapies: TPM203, Argenx BVBA, DSG3-CAART, and others
  • Pemphigus Vulgaris Therapeutic Assessment: Pemphigus Vulgaris current marketed and Pemphigus Vulgaris emerging therapies
  • Pemphigus Vulgaris Market Dynamics: Pemphigus Vulgaris market drivers and Pemphigus Vulgaris market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Pemphigus Vulgaris Unmet Needs, KOL’s views, Analyst’s views, Pemphigus Vulgaris Market Access and Reimbursement 


Pemphigus Vulgaris Market Unmet Needs

  • Challenges in diagnoses
  • Development of novel therapies
  • Limitations in gene therapy
  • Poor disease understanding
  • Clinical biomarkers


Table of Contents 

1. Pemphigus Vulgaris Market Report Introduction

2. Executive Summary for Pemphigus Vulgaris

3. SWOT analysis of Pemphigus Vulgaris

4. Pemphigus Vulgaris Patient Share (%) Overview at a Glance

5. Pemphigus Vulgaris Market Overview at a Glance

6. Pemphigus Vulgaris Disease Background and Overview

7. Pemphigus Vulgaris Epidemiology and Patient Population

8. Country-Specific Patient Population of Pemphigus Vulgaris 

9. Pemphigus Vulgaris Current Treatment and Medical Practices

10. Pemphigus Vulgaris Unmet Needs

11. Pemphigus Vulgaris Emerging Therapies

12. Pemphigus Vulgaris Market Outlook

13. Country-Wise Pemphigus Vulgaris Market Analysis (2019–2032)

14. Pemphigus Vulgaris Market Access and Reimbursement of Therapies

15. Pemphigus Vulgaris Market Drivers

16. Pemphigus Vulgaris Market Barriers

17.  Pemphigus Vulgaris Appendix

18. Pemphigus Vulgaris Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight


To know more about Pemphigus Vulgaris treatment, visit @ Pemphigus Vulgaris Medications

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States